We aimed at investigating the effect of erdosteine administration on amikacin induced visual evoked potentials (VEPs) alterations in rats.
Methods:
For this purpose, forty male Wistar rats were divided into 4 groups: control, amikacin treated, erdosteine treated, and amikacin + erdosteine treated. Amikacin (600 mg/kg/day) was applied as a single dose of intramuscular injection for 14 days, and 10 mg/kg/day erdosteine was given by gastric gavage for the same period. We recorded all VEP components and measured plasma thiobarbituric acid reactive substance (TBARS) levels in all groups.
Results:
Amikacin increased the latencies of all VEP components (P1, N1, P2, N2, and P3) and elevated plasma TBARS levels compared with control and erdosteine treated rats (p < 0,01). However, prolonged latencies of VEP components in amikacin treated rats returned to control levels after erdostein administration. Treatment of amikacin and erdosteine together significantly decreased plasma TBARS levels (0.05 ± 0.018 nmol/g protein) compared with amikacin group (0.12 ± 0.038 nmol/g protein).
Conclusions:
These results show that erdosteine has a protective effect on amikacin induced changes in the visual system.
Get full access to this article
View all access options for this article.
References
1.
YazarE., ElmasM., AltunokV.et al.Effects of aminoglycoside antibiotics on renal antioxidants, malondialdehyde levels, and some serum biochemical parameters. Can. J. Vet. Res., 67:239–240. 2003.
ParlakpinarH., OzerM.K., SahnaE.et al.Amikacin-induced acute renal injury in rats: protective role of melatonin. J. Pineal Res., 35:85–90. 2003.
6.
AbujaP.M., AlbertiniR.Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin. Chim. Acta, 306:1–17. 2001.
7.
KlemensJ.J., MeechR.P., HughesL.F.et al.Antioxidant enzyme levels inversely covary with hearing loss after amikacin treatment. J. Am. Acad. Audiol., 14:134–143. 2003.
8.
ShaheenA.A., HamdyM.A., Kheir-EldinA.A.et al.Effect of pretreatment with vitamin E or diazepam on brain metabolism of stressed rats. Biochem. Pharmacol., 46:194–197. 1993.
9.
ConlonB.J., AranJ.M., ErreJ.P.et al.Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant alpha-lipoic acid. Hear. Res., 128:40–44. 1999.
10.
SugasawaK., Charletde, SauvageR.et al.Changes in electrovestibular brainstem responses after aminoglycoside intoxication in guinea pigs. Clin. Neurophysiol., 112:1357–1363. 2001.
11.
DemiralayR., GürsanN., ErdemH.The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells. J. Cell Biochem., 104:1740–1746. 2008.
BragaP.C., Dal, SassoM., ZuccottiT.Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung, 50:739–746. 2000.
14.
MorettiM., MarchioniC.F.An overview of erdosteine antioxidant activity in experimental research. Pharmacol. Res., 55:249–254. 2007.
CicekE., SutcuR., GokalpO.et al.The effects of isoniazid on hippocampal NMDA receptors: protective role of erdosteine. Mol. Cell. Biochem., 277:131–135. 2005.
18.
HudnellH.K., BoyesW.K.The comparability of rat and human visual-evoke potentials. Neurosci. Biobehav. Rev., 15:159–164. 1991.
19.
LehmanD.M., HarrisonJ.M.Flash visual evoked potentials in the hypomyelinated mutant mouse shiverer. Doc. Ophthalmol., 104:83–95. 2002.
20.
HudnellH.K., BoyesW.K., OttoD.A.Rat and human visual evoked potentials recorded under comparable conditions: a preliminary analysis to address the issue of predicting human neurotoxic effects from rat data. Neurotoxicol. Teratol., 12:391–398. 1990.
21.
HetzlerB.E., BoyesW.K., CreasonJ.et al.Temperature dependent changes in visual evoked potentials of rats. Electroencephalogr. Clin. Neurophysiol., 70:137–154. 1988.
22.
WasowiczW., NeveJ., PeretzA.Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin. Chem., 39:2522–2526. 1993.
23.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72:248–254. 1976.
24.
KaynarK., GulS., ErsozS.et al.Amikacin-induced nephropathy: is there any protective way?Ren. Fail., 29:23–27. 2007.
25.
GallowayG., RamsayA., JordanK.et al.Macular infarction after intravitreal amikacin: mounting evidence against amikacin. Br. J. Ophthalmol., 86:359–360. 2002.
KumarA., DadaT.Preretinal haemorrhages: an unusual manifestation of intravitreal amikacin toxicity. Aust. N. Z. J. Ophthalmol., 27:435–436. 1999.
28.
ChaudharyM., SoniA., DwivediV.K.Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice. Curr. Clin. Pharmacol., 3:211–214. 2008.
29.
BazanN.G., MarcheselliV.L., Cole-EdwardsK.Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. N. Y. Acad. Sci., 1053:137–147. 2005.
30.
DerinN., AkpinarD., YargicogluP.et al.Effect of alpha-lipoic acid on visual evoked potentials in rats exposed to sulfite. Neurotoxicol. Teratol., 31:34–39. 2009.
31.
OzerolE., BilgicS., IrazM.The protective effect of erdosteine on short-term global brain ischemia/reperfusion injury in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 33:20–24. 2009.
32.
SahinM., CamH., OlgarS.et al.Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver. Mol. Cell. Biochem., 291:155–160. 2006.
33.
FadillioğluE., ErdoğanH.Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol. Res., 47:317–322. 2003.
